Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor

Chinese Medical Journal

Volumn 124, Issue 1, 2011, Pages 89-94

  Dai, Qi Ming ^a   Lu, Jing ^a   Liu, Nai Feng ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Heart failure; HMG CoA reductase inhibitors; Myocardial fibrosis; Rho rho kinase

Indexed keywords

CHOLESTEROL; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; FLUINDOSTATIN; GLUCOSE; MESSENGER RNA; RHO FACTOR; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; MALE; MYOCARDIAL INTERSTITIAL FIBROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; BLOTTING, WESTERN; CHOLESTEROL; CONNECTIVE TISSUE GROWTH FACTOR; FATTY ACIDS, MONOUNSATURATED; FIBROSIS; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MYOCARDIUM; RANDOM ALLOCATION; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78651244958     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.01.017     Document Type: Article

References (31)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
2. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
3. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000; 80: 513-527.
4. Marwick TH. Diabetic heart disease. Heart 2006; 92: 296-300.
5. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-3223.
6. Asghar O, Al-sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, et al. Diabetic cardiomyopathy. Clin Sci 2009; 116: 741-760.
7. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
8. Monzack EL, Gu X, Masters KS. Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment. Arterioscler Thromb Vasc Biol 2009; 29: 246-253.
9. Cicha I, Goppelt-Struebe M, Muehlich S, Yilmaz A, Raaz D, Daniel WG, et al. Pharmacological inhibition of RhoA signaling prevents connective tissue growth factor induction in endothelial cells exposed to non-uniform shear stress. Atherosclerosis 2008; 196: 136-145.
10. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
11. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
12. Kamiyama M, Utsunomiya K, Taniguchi K, Yokota T, Kurata H, Tajima N, et al. Contribution of Rho A and Rho kinase to platelet derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb 2003; 19: 117-123.
13. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta Y, et al. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006; 291: H2237-H2245.
14. Peng F, Zhang B, Wu D, Ingram AJ, Gao B, Krepinsky JC. TGFβ-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Renal Physiol 2008; 295: F153-F164.
15. Tan JT, McLennan SV, Song WW, Lo LW, Bonner JG, Williams PF, et al. Connective tissue growth factor inhibits adipocyte differentiation. Am J Physiol Cell Physiol 2008; 295: C740-C751.
16. Hughes JM, Kuiper EJ, Klaassen I, Canning P, Stitt AW, Va n Bezu J, et al. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 2007; 50: 1089-1098.
17. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 2004; 165: 2033-2043.
18. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002; 105: 1861-1870.
19. Shiomi T, Tsutsui H, Ikeuchi M, Matsusaka H, Hayashidani S, Suematsu N, et al. Streptozotocin induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 2003; 42: 165-172.
20. Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, Sánchez-López E, Rodríguez-Vita J, Esteban V, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007; 50: 377-383.
21. Kang B Y, Wang W, Palade P, Sharma SG, Mehta JL. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 2009; 54: 327-334.
22. Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, Gross O. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 2007; 22: 1062-1069.
23. Liang XM, Otani H, Zhou Q, Tone Y, Fujii R, Mune M, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai rats. Nephrol Dial Transplant 2007; 22: 2156-2164.
24. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709-2718.
25. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 2007; 30: 439-449.
26. Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008; 149: 380-388.
27. Song Y, Cai L, Lu C. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 2004; 76: 66-75.
28. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 568: 242-247.
29. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-873.
30. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-β is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1323-L1332.
31. Ou XM, Feng YL, Wen FQ, Huang XY, Xiao J, Wang K, et al. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice. Chin Med J 2008; 121: 1821-1829.